Easier access to care for Veterans with memory loss.
Official title: Increasing Access to Care: An Advanced Virtual Care Delivery Protocol to Deliver Diagnostic and Therapeutic Services to Underserved Veterans With ADRD
Run by VA Pittsburgh Healthcare System · NCT07117162 · Data updated 2026-11-12
This program tests whether a telehealth-based care protocol can help Veterans with mild cognitive impairment or early dementia get screened and considered sooner for amyloid-targeting treatments.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | VA Pittsburgh Healthcare System Federal |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Status | Recruiting |
| Started | October 29, 2025 |
| Main results expected | June 2027 |
| Study ends | June 2027 |
| Registry record updated | July 17, 2026 |
| Trial ID | NCT07117162 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Veterans enrolled in VA care who live at home, are 18 or older, English-speaking, able to consent, and have mild cognitive impairment or mild dementia with a 5-minute telephone MoCA >7.
✕Probably not a fit
Patients in institutional settings (such as nursing homes), those not enrolled in VA care, non-English speakers, or those with more advanced dementia or who do not meet mAb therapy criteria are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized controlled trial at VA Pittsburgh will enroll Veterans with mild cognitive impairment or early dementia due to suspected or confirmed Alzheimer disease. Eligible participants must be enrolled in VA care, live at home, be 18 or older, speak English, be able to consent, and have a 5-minute telephone MoCA score >7. The intervention is an ADRD care delivery protocol that integrates telehealth visits, expedited advanced diagnostics, and streamlined workflows to speed screening for eligibility for amyloid-targeting monoclonal antibody therapies. Outcomes will compare time-to-screening and access metrics between the integrated protocol and usual VA care pathways.
Why it matters
Potential benefit: If successful, the protocol could shorten wait times and speed access to amyloid-targeting therapies for eligible Veterans, enabling earlier treatment decisions.
How similar studies have gone: Telehealth and care-delivery models have improved access in other settings, but combining rapid diagnostics and streamlined workflows specifically to expedite amyloid-targeted therapy screening is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of mild cognitive impairment or mild dementia due to suspected or confirmed AD with a 5 minute telephone MoCA score \>7 * Meets VA MUE inclusion/exclusion criteria for mAb therapy for AD * Enrolled in VA care * Lives in a home setting (i.e., not in an institutional setting such as a nursing home, Community Living Center, or hospital) * Has a working telephone * 18 years and older * Able to communicate in English * Willing to give informed consent. Exclusion Criteria: * None
Where it's running
-
VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Alison O'Donnell, DO, MPH
- Email: alison.odonnell2@va.gov
- Phone: 412-822-1020
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Tau changes after hip or knee replacement surgery
Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.
-
Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia
This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.
-
Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s
We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.
-
Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease
This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.
-
Testing LY4405094 in healthy people and people with Alzheimer’s disease
This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.